Products
AI AGENTS
INTELLIGENCE SUITE
API, MCP & INTEGRATION
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
Patsnap Eureka Platform
IP Search Agents
IP Drafting Agents
Engineering Agents
Find Solutions with TRIZ
Life Sciences Agents
Materials Agents
SEP Agents
Patsnap Eureka Desktop
BetaAnalytics
IP IntelligenceHiro for Analytics
Synapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisProfessional Services
Open Platform
Developer Center
Customer Stories
Newsroom
Blog
2026 R&D Benchmark Report
Glossary
Free tools
NEWWebinars & Training
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
The form could not load. Please try again or email our team.
[email protected]No credit card required
Already have an account? Log In
To start using Patsnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report Capivasertib (AZD5363) targets the PI3K/AKT/PTEN pathway in HR+/HER2- breast cancer. Explore the CAPItello-291 Phase III rationale, IP signals, and combination strategy.
Article | Report An overview of tarlatamab's DLL3-targeting BiTE mechanism, the DeLLphi-312 first-line SCLC trial design, and IO + bispecific combination rationale for extensive-stage SCLC.
Article | Report Patritumab deruxtecan (HER3-DXd) is reshaping post-EGFR TKI NSCLC treatment. Explore the patent race, clinical data, and Daiichi Sankyo/AstraZeneca strategy.
Article | Report Explore the 2026 wearable continuous health monitor technology landscape: key patent trends, R&D signals, and innovation intelligence from PatSnap Eureka.
Article | Report LAG-3 combination therapy relatlimab plus nivolumab vs. pembrolizumab in adjuvant melanoma: checkpoint mechanisms, clinical context, and IP landscape analysis.
Article | Report TERN-501 is a selective THRβ agonist developed by Terns Pharmaceuticals for MASH. Explore its patent landscape, mechanism, and competitive positioning against resmetirom.
Article | Report Icotrokinra (JNJ-2113) is the first oral IL-23 receptor peptide inhibitor in Phase III for psoriasis. Explore J&J's patent strategy and the race to challenge injectable biologics.
Article | Report Iptacopan vs. ravulizumab in PNH: how oral Factor B inhibition reshapes complement therapy, hemoglobin endpoints, and the competitive landscape.
Article | Report How GSK depemokimab and tezepelumab are reshaping severe asthma treatment beyond eosinophil-high phenotypes — a deep dive into the alarmin axis competitive race.
Article | Report How amivantamab redefined EGFR exon 20 insertion NSCLC treatment — and why the HER2 pipeline is racing to replicate that blueprint. Patent and clinical data analysis.
Article | Report How luspatercept's ActRIIB ligand trap and BMS's emerging RSK3 inhibitors are redefining anemia treatment in lower-risk MDS and beta-thalassemia beyond transfusion dependence.
Article | Report How AI-based optical emission spectroscopy improves real-time process control in plasma etching — what semiconductor fabs need to know before the data is in.
Article | Report Next-generation GLP-2 analogs are reshaping short bowel syndrome treatment beyond teduglutide. Explore the patent pipeline, key players, and what comes next.
Article | Report How engineers manage version control and traceability for safety-critical embedded software under IEC 62443 — key standards, lifecycle approaches, and toolchain best practices.
Article | Report Dato-DXd vs. SG in TNBC: compare TROP2 ADC mechanisms, linker-payload design, clinical signals, and IP landscape for datopotamab deruxtecan and sacituzumab govitecan.